Gabapentin Capsule
Product Images NDC 71205-317

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71205-317). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration showing a formula for calculating creatinine clearance (CLCr). The formula incorporates patient age in years, weight in kilograms, serum creatinine levels in mg/dL, and includes a multiplication factor of 0.85 for female patients.*

FDA Label Image

71205-317-90 (Container100mg500cc)

Label for Gabapentin 100 mg capsules by Proficient Rx LP. The label indicates 90 capsules per bottle and states each capsule contains Gabapentin USP 100 mg. Packaging details include NDC 71205-317-90 and manufacturer Strides Shasun Limited Unit II, India. The capsules are described as hard gelatin with white opaque cap and body, imprinted with AHD on the cap and 100 on the body.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of gabapentin, showing a cyclohexane ring connected to two side chains, one with an amino group (CH2NH2) and the other with a carboxylic acid group (CH2CO2H).*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph depicting mean pain scores over eight weeks, comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis indicates mean pain scores ranging from 0 to 10. Two phases are noted: a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

Line graph showing mean pain score over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period, with Gabapentin groups showing lower mean pain scores than placebo across the timeline.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) doses in two separate studies. Study 1 shows 12% PBO and 29% GBP 3600 responders; Study 2 shows 14% PBO, 32% GBP 1800, and 34% GBP 2400 responders, with statistical significance markers (p < 0.01 and p < 0.001).*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot chart displaying the difference percentage on the vertical axis versus daily dose in milligrams on the horizontal axis. Three studies, labeled Study A, Study B, and Study C, are represented by black, gray, and white squares respectively, showing varying percentage differences at daily doses of 600, 900, 1200, and 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.